Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Radiotherapy 15Lapatinib 15Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Immunohistochemistry 9Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8Biopsy 8exemestane 7Vorinostat 7Magnetic Resonance Spectroscopy 7Letrozole 7Immunoenzyme Techniques 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Goserelin 6Fluorodeoxyglucose F18 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × dinaciclib × Breast × Clear all
NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡